The nanocomposite encapsulated mitoxantrone (MTX, a genotoxic drug/topoisomerase II inhibitor) and its surface was functionalized with a peptide to target interleukin-13 receptor alpha 2 (IL13Rα2), which is frequently overexpressed in GBM cells [261]. The gene discussed is IL13RA2; the disease is glioblastoma.